Interaksjoner mellom statiner og makrolidantibiotika

Tidsskrift for den Norske Laegeforening

Volumn 127, Issue 12, 2007, Pages 1660-1661

  Molden, Espen ^a   Andersson, Kirsti Svendsen ^b   Jacobsen, Dag ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250742590     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Molden E, Åsberg A. Metabolismeinteraksjoner med statiner. Tidsskr Nor Lægeforen 2001; 121: 189-93.
2. Molden E. Variability in cytochrome P450-mediated metabolism of cardiovascular drugs: Clinical implications and practical attempts to avoid potential problems. Heart Drug 2004; 4: 55-79.
3. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 441-57.
4. Antons KA, Williams CD, Baker SK et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9.
5. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after co-administration of macrolide antibiotics in two patients. Pharmacotherapy 2007; 27: 603-7.
6. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140-6.
7. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31.
8. Kahri AJ, Valkonen MM, Vuoristo MK et al. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother 2004; 38: 719.
9. Trieu J, Emmett L, Perera C et al. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. Clin Nucl Med 2004; 29: 803-4.
10. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother 2005; 39: 1760-1.
11. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107.
12. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003; 37: 808-11.
13. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 2003; 17: 207-10.
14. Schech S, Graham D, Staffa J et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007; 16: 352-8.
15. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40: 833-68.
16. Periti P, Mazzei T, Mini E et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106-31.